Background: Platinum-based chemoradiation (CCRT) is the standard treatment for Locally Advanced Head and Neck Squamous-Cell Carcinoma (LAHNSCC). Cetuximab/RT (CET/RT) is an alternative treatment option to CCRT. The efficacy of induction chemotherapy (IC) followed by chemoradiation compared to chemoradiation alone has not been demonstrated in randomized clinical trials. The goals of this phase II-III trial were to assess: (i) the overall survival (OS) of IC versus no-induction (no-IC) and (ii) the Grade 3-4 in-field mucosal toxicity of CCRT versus CET/RT. The present paper focuses on the analysis of efficacy.
Background: Platinum-based chemoradiation (CCRT) is the standard treatment for Locally Advanced Head and Neck Squamous-Cell Carcinoma (LAHNSCC). Cetuximab/RT (CET/RT) is an alternative treatment option to CCRT. The efficacy of induction chemotherapy (IC) followed by chemoradiation compared to chemoradiation alone has not been demonstrated in randomized clinical trials. The goals of this phase II-III trial were to assess: (i) the overall survival (OS) of IC versus no-induction (no-IC) and (ii) the Grade 3-4 in-field mucosal toxicity of CCRT versus CET/RT. The present paper focuses on the analysis of efficacy.
Materials and methods:
Patients with LAHNSCC were randomized to receive concomitant treatment alone [CCRT (Arm A1) or CET/RT (Arm A2)], or three cycles of induction docetaxel/cisplatin/5 fluorouracil (TPF) followed by CCRT (Arm B1) or followed by CET/RT (Arm B2). The superiority hypothesis of OS comparison of IC versus no-IC (Arms B1 þ B2 versus A1 þ A2) required 204 deaths to detect an absolute 3-year OS difference of 12% (HR 0.675, with 80% power at two-sided 5% significance level).
Results: 414 out of 421 patients were finally analyzed: 206 in the IC and 208 in the no-IC arm. Six patients were excluded because of major violation and one because of metastatic disease at diagnosis. With a median follow-up of 44.8 months, OS was significantly higher in the IC arm (HR 0.74; 95% CI 0.56-0.97; P ¼ 0.031). Complete Responses (P ¼ 0.0028), Progression Free Survival (P ¼ 0.013) and the Loco-regional Control (P ¼ 0.036) were also significantly higher in the IC arm. Compliance to concomitant treatments was not affected by induction TPF.
Introduction
Squamous-cell carcinoma of the head and neck represents 5% of newly diagnosed cancers in adults and more than 550 000 new cases are predicted annually worldwide [1] . Most patients present loco-regionally advanced disease (LAHNSCC) not suitable for radical resection or low surgical curability. Phase III studies and individual patient data Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC) [2, 3] have shown that concomitant platinum-based chemoradiotherapy (CCRT) is the optimal treatment for LAHNSCC.
In 2006, a phase III trial comparing radiotherapy (RT) alone versus cetuximab/RT (CET/RT) showed that CET/RT also provides superior overall survival (OS) and loco-regional control (LRC) [4, 5] .
Induction chemotherapy (IC) has a proven role in organ preservation and in reducing distant failure [2, 3, 6] , however, its ability to prolong OS has not been demonstrated. The MACH-NC showed that IC cisplatin/5-fluorouracil (PF) followed by local treatment was associated with a small but significant improvement in OS [hazard ratio (HR) 0.90; 95% CI 0.82-0.99] and in distant failures (HR 0.63; 95% CI 0.45-0.89) [2, 3] . In a recent MACH-NC update, induction PF plus a taxane [6] increased progression free survival (PFS) (HR 0.78; 95% CI, 0.69-0.87) and OS versus PF (HR 0.72; 95% CI 0.63-0.83).
Our trial was designed to assess the OS of concomitant treatment with or without IC and the in-field mucosal toxicity of CCRT versus CET/RT. This report is focused on the comparison of IC versus no-IC.
Patients and methods

Study design
This is a multicenter, open-label, randomized phase II-III trial. In the first part [phase II randomized part (XRP6976-F/2501)] patients were randomized to receive CCRT or IC followed by the same CCRT. Since the target difference of 15% in centrally reviewed radiological complete responses (CR) in favor of IC had been achieved [7] , the trial continued as a phase III (NCT01086826), as pre-planned. Since CET/RT combination had become an alternative treatment option to CCRT [4, 5] within the study design timeframe, a 2Â2 randomization was introduced for the phase III part of the trial according to the reciprocal control design [8] . Single-step double randomization, was centrally managed, computergenerated, with a permuted-block scheme and a 1:1 ratio, stratified by T (T1-2 versus T3-4), N (N0-1 versus N2-3), and primary site (oral cavity/oropharynx versus hypopharynx). Once assigned to the IC or no-IC arm, the randomization to CCRT or CET/RT was stratified by IC assignment.
An Independent Data Monitoring Committee (IDMC) reviewed accrual, safety, and aggregate data on efficacy.
Eligible patients aged !18 years had to have a histological/cytological previously untreated stage III-IV LAHNSCC of the oral cavity, oropharynx, hypopharynx, ECOG Performance Status of 0-1, life expectancy !6 months, adequate bone marrow and organ function; no peripheral neuropathy, altered hearing !G2, or weight loss >20% in the previous 3 months.
Patients were deemed unsuitable for radical surgery after evaluation of a multidisciplinary team. Inoperability criteria were technical reasons (tumor fixation/invasion to either base of the skull, cervical vertebrae, nasopharynx, or fixed lymph nodes) or low surgical curability (T3-4, N2-3 excluding T1N2). Patients unresectable due to medical conditions were not eligible.
RT was delivered according to the Italian national guidelines on 'Quality guarantee in Radiotherapy' (Istituto Superiore di Sanit a, rapporti ISTISAN 02/20, in Italian).
The study was conducted in accordance with the Declaration of Helsinki and the protocol was approved by Institutional Ethic Committees . All patients provided written informed consent.
Treatment plan
Patients were randomized to receive concomitant treatment alone [CCRT (arm A1) or CET/RT (arm A2)] or three cycles of IC followed by CCRT (arm B1) or followed by CET/RT (arm B2). The CET/RT arms were numerically unbalanced in accordance with the revised trial design.
Standard-fractionated RT (2 Gy/day, 5 days/week) of 70 Gy was delivered to the primary tumor and !60 Gy to the neck depending on whether a neck dissection was indicated/planned. 3D conformal radiotherapy or IMRT were allowed.
The CCRT arm consisted of two cycles of cisplatin 20 mg/m 2 from days 1 to 4 plus 5-fluorouracil 800 mg/m 2 /day, 96-h continuous infusion, administered during weeks 1 and 6 of the radiation treatment.
In the CET/RT arm, cetuximab was initiated 1 week before RT at 400 mg/m 2 loading dose and followed by 250 mg/m 2 weekly, for 7 weeks.
In the IC arms, three cycles of docetaxel 75 mg/m 2 day 1, cisplatin 80 mg/m 2 day 1 and 5-fluorouracil 800 mg/m 2 /day 96-h continuous infusion (TPF) were administered every 3 weeks with antibiotic prophylaxis after each cycle. Within 3-5 weeks after IC, patients received CCRT or CET/RT provided there was no disease progression.
Prophylactic neck dissection was planned for stage N2-N3 patients achieving pathological CR at the primary site and radiological CR at the neck. Salvage surgery was considered for residual disease after treatment.
End points
OS of no-IC versus IC (from the date of randomization until death from any cause) was the primary efficacy end point. Survival was also expressed as the proportion of patients alive after 3 years.
Secondary efficacy endpoints included: response rate (RR) 6-8 weeks after concomitant treatment and 3-4 weeks after IC, according to the RECIST criteria; LRC defined as the absence of loco-regional progression or death due to loco-regional disease (deaths due to primary cancer without documented recurrence and/or deaths from unknown causes were attributed to loco-regional disease) [9] ; PFS was calculated from randomization to progression, second primary or death from any cause.
Toxicity was graded using the Common Toxicity Criteria for Adverse Events (version 2.0).
Statistical methods
The trial was initially designed to have a power of 0.85 to detect an absolute difference of 15% in 3-year OS (from 45% to 60%), corresponding to a HR of 0.64, a ¼ 0.05, two-sided. At the planned interim analysis (June 2010), the IDMC suggested increasing the sample size according to the good steady-level of recruitment and to the preliminary safety data. A more conservative HR of 0.675 (12% difference in 3-year OS, from 52.5% to 64.5%), was therefore adopted (power 0.80, a ¼ 0.05, two-sided). Consequently, 420 patients (instead of 350) had to be randomized to observe at least 204 events. The protocol was amended accordingly (July 2010).
Kaplan-Meier curves for survival with the Mantel-Cox version of the log-rank test were compared. Cox proportional hazards model was used to estimate treatment effect adjusted for prognostic factors [age, T stage, N stage, ECOG-PS, site, phase of recruitment (II versus III), type of concomitant treatment (CCRT versus CET/RT)]. In the analysis of LRC, deaths not caused by loco-regional disease and distant relapses were regarded as competing events [10] .
The differences in relative effect size according to the type of concomitant treatment were described by forest plots of HR and relative confidence interval at 95% level (95% CI), and tested for interaction.
Analyses were conducted according to the Intention-To-Treat (ITT) except for compliance, safety and RR, performed considering patients in the arm of treatment they actually received.
Results
Patient characteristics
421 patients were randomized in 48 centers. 101 entered the phase II part of the trial between January 2003 and January 2006 while the other 321 were randomized between March 2008 and April 2012. Final analysis was conducted on 414 patients. Seven patients were not included: one due to metastatic disease and six as outcome information were not submitted.
206 patients were randomized to the no-IC arm and 208 to the IC arm (Figure 1) .
Baseline patient characteristics were well balanced (Table 1) .
Safety 204 patients were evaluable for toxicity during IC (supplementary Table S1 , available at Annals of Oncology online) and 384 during concomitant treatment ( Table 2) . During induction TPF, neutropenia (27.5%) was the most relevant G3-4 toxicity; febrile neutropenia was 11%. During Original article Annals of Oncology concomitant treatment, neutropenia G3-4 was significantly higher in the IC arm (4% versus 1%, P ¼ 0.038). No significant differences were observed in G3-4 in-field mucositis and dermatitis (34.5% versus 41% and 14% versus 15%, respectively) and in other G3-4 toxicities, apart from skin-rash resulting from cetuximab administration in the no-IC arm (6% versus 1.5%; P ¼ 0.028). The maximum grade of renal toxicity observed was G2 in three patients. Twelve early deaths (death within 30 days of last treatment administration) occurred: five in the IC arm and seven in the no-IC arm. The causes of early deaths were progressive disease (1), toxicity [5: 3 hematological toxicities (2 in the IC), 1 gastric perforation (IC arm) and 1 sepsis (IC arm)], unrelated to study treatment (3) and unknown (3).
Compliance
194 patients completed the three planned IC cycles. About nine patients had to interrupt and five patients never started IC.
Compliance with concomitant treatment, independently from the type of concomitant strategy, was similar in the IC and no-IC arms (supplementary Table S2 , available at Annals of Oncology online). No significant differences were observed in completion of the concomitant treatment (PF/cetuximab), median RT dose and duration and number of patients who required RT interruption more than three consecutive days.
Response rate
196 patients (94%) were evaluable for response to IC and 372 (90%) were evaluable after concomitant treatment.
After IC, overall RR (ORR) was 76%. ORRs after concomitant treatment were similar, 80% versus 81%, while CRs were significantly higher in the IC arm: 42.5% versus 28%, P ¼ 0.0028 (supplementary Table S3 , available at Annals of Oncology online). More patients in the IC arm (8.5% versus 4%) received prophylactic neck dissection (N2-N3 initial stage). Salvage surgery was performed in 21.5% of patients in the IC arm versus 26.5% in the no-IC arm (P ¼ 0.229) (supplementary Figure S1 , available at Annals of Oncology online).
Efficacy
After a median follow-up of 44.8 months 204 patients had died: 97 in the IC arm and 107 in the no-IC arm (supplementary Table  S4 Tables S5 and S6 , available at Annals of Oncology online).
Loco-regional failure ( Figure 2C ) was lower in the IC arm: 41% versus 48% (HR 0.74; 95% CI 0.55-0.98; P ¼ 0.036) with a borderline advantage at multivariate analysis (P ¼ 0.06, supplementary Table S7 , available at Annals of Oncology online). Distant failure, with or without loco-regional recurrence, was 13% in the IC arm versus 16% in the no-IC arm (HR 0.76; 95% CI 0.46-1.25; P ¼ 0.274) ( Figure 2D) .
The potential different effect of IC in relation to the primary tumor site and to the subsequent concomitant strategy was also evaluated. Apparently, the effect was marked in patients with non-oropharynx cancer (supplementary Figure S2 , available at Annals of Oncology online) and in patients receiving CET/RT after IC (HR 0.57; 95% CI 0.35-0.92) (supplementary Figure S3 , available at Annals of Oncology online). The interaction test did not reach the statistical significance (P ¼ 0.088). A similar trend was observed for PFS (supplementary Figure S4 , available at Annals of Oncology online).
Discussion
Our trial aimed to test the hypothesis that adding induction TPF to concomitant treatment (CCRT or CET/RT) could improve OS. The TPF and CCRT regimen derived from our previous feasibility study [11] based on the results of a GORTEC trial [12] .
In accordance with study design, time-related events (OS, PFS, LRC) are shown only for IC versus no-IC comparison. Since the CET/RT arms have a shorter follow-up time and less patients than CCRT arms, the comparison of the two concomitant treatments in terms of time-related events is likely to be heavily biased. For these reasons CCRT versus CET/RT were compared only in terms of G3-4 acute toxicity (co-primary end point). This is the first trial showing a significant OS benefit for IC consistent with a significant improvement in CRs and PFS with a borderline improvement in LRC.
We believe that the positive effect of IC on OS could be related to a combined effect on local and distant control. The hypothesis that induction TPF interacts positively with concomitant treatment, increasing both CRs and LRC, seems consistent with the MACH-NC meta-analysis [6] in which induction TPF was associated with a better LRC over PF.
Recently, three phase III trials [13] [14] [15] failed to demonstrate a survival benefit for the addition of IC to CCRT, although in two trials [13, 14] the planned accrual was not achieved.
The OS reported in our trial for the concomitant arm (3-year OS 46.5%) is similar to that reported in European trials [15] [16] [17] and lower than that observed in US trials [9, 13, 14, 20] . Studies including US and non-US population had an intermediate OS [4, 5, 18] . It is our opinion that US patients are selected for fewer comorbidities and these characteristics, together with higher incidence of HPV-related cancer in USA, are predictive of better outcomes.
The OS multivariate Cox analysis confirmed the prognostic value for PS, T stage and oropharynx primary sites but not for N stage. This observation seems consistent with a report on oropharynx cancer [19] , in which nodal level rather than nodal stage correlated with prognosis. Since our trial was designed in the early 2000s, HPV analysis was not planned. Exploratory analysis for OS showed a higher effect of IC in non-oropharynx cancer, however these results should be interpreted with caution. The retrospective evaluation of HPV is ongoing and will enable us to better assess the results of our trial.
Subgroup analysis showed a possible superior effect of IC when followed by CET/RT rather than CCRT. Although the interaction test was not statistically significant (P ¼ 0.088), we cannot exclude a possible interaction due to the lack of statistical power for this evaluation. The possible interaction was only quantitative, not qualitative, since a survival benefit was observed for IC in each concomitant treatment. These data should be interpreted with caution and were only for explorative purpose.
Currently, we have no explanation for the possible different effect of IC when followed by CCRT or CET/RT. We know that combining CCRT and a biological drug simultaneously is not a winning strategy [20] and we can only speculate a possible higher sensitizing effect of cetuximab on cancer cells surviving the platinum-based IC. Whether induction TPF might have different efficacy depending on the subsequent concomitant treatment delivered is an intriguing issue and needs further exploration.
With regard to safety to concomitant treatment, G3-4 neutropenia was significantly higher, but negligible, in patients receiving IC. Conversely, G3-4 non-hematological toxicities were not worse and compliance was similar too. Good compliance to IC and to the subsequent concomitant treatment might be attributed to the schedule and doses of the induction TPF and of the CCRT regimen adopted [11] .
As discussed in our previous publication [7] , we believe that the comparator CCRT arm should be considered appropriate. In our trial, two cycles of concomitant PF were planned with the aim of limiting the adverse effects of concomitant chemotherapy, unplanned dose reduction and RT treatment breaks. Retrospective analyses in LAHNSCC seem to suggest that for cisplatin monotherapy 200 mg/m 2 total dose could be as effective as 300 mg/m [2, 9, 21] . In our trial the cumulative dose of cisplatin is 160 mg/m 2 , however 5FU was added with the aim of enhancing the activity of the concomitant treatment both on loco-regional and distant control.
Currently, CET/RT is considered an alternative treatment option to CCRT. The results of phase III trials comparing these two concomitant strategies are not yet available and the retrospective comparisons have the limitations of selection bias and heterogeneous population [22] . Some data have been provided by a randomized phase-II larynx preservation trial comparing CCRT or CET/RT in responding to induction TPF patients [23] . No differences were observed in the organ preservation end points although LRC seemed to be better in the CCRT arm. To learn more about the possible different efficacy of these two concomitant strategies we have to wait for the results of the ongoing phase III trials.
In conclusion, on the basis of our findings, adding induction TPF to concomitant treatment significantly improves CRs, PFS and OS without compromising compliance to the concomitant treatments. The positive effect in LRC also appears to be a key component of the IC strategy. The degree of benefit may differ according to the type of the subsequent concomitant strategies. Since this trial was not designed to investigate questions different from the efficacy comparison of IC versus no-IC, we are not able to establish whether the benefit of IC is limited to specific subgroups of patients or applies to the entire population.
Although currently IC cannot be considered the standard of care of LAHNSCC, nonetheless it should be regarded as an option for poor prognosis patients. Further efforts should also be made to identify the best concomitant treatment to be administered after IC.
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